RDNT

Business Context and Reporting Period

This Form 10-Q covers Primedex Health Systems, Inc. (operating primarily through its subsidiary Radnet, Inc.) for the quarter and six months ended April 30, 1997. The company operates diagnostic imaging centers and provides radiology management services. The reporting period includes significant restructuring activities, including the closure of the Parkside facility and the sale of assets to Diagnostic Health Services, Inc. (DHS).

Key Financial Metrics

Note: Net Income for the six months ended April 30, 1997, includes an extraordinary gain of $5,593,832 from the sale of assets to DHS. Without this gain, the net loss would have been approximately $10.27 million.

Material Changes vs. Prior Period

• Revenue Growth: Net revenue increased by approximately 28.5% year-over-year, driven primarily by the inclusion of Diagnostic Imaging Services, Inc. (DIS) operations, which contributed roughly $9.35 million in net revenue.
• Operating Performance: The company shifted from an operating income of $2.27 million in the prior year to an operating loss of $5.36 million. This deterioration was caused by a $4.95 million impairment loss related to the Parkside facility closure and increased bad debt provisions (rising from $0.64 million to $1.22 million).
• Debt Reduction: Total debt decreased by approximately $17.5 million. Proceeds from the sale of DIS assets ($16 million) were used to reduce lines of credit and pay down notes payable.
• Liquidity Improvement: Despite a net cash outflow from operating activities of $1.4 million, the company's working capital deficit improved by nearly $10 million due to the cash infusion from asset sales.

Outlook, Risks, and Unusual Items

Unusual Items and Restructuring

• Asset Sales: The company sold four hospital-based MRI facilities and its Ultrasound Division to DHS for approximately $16 million, recognizing a $5.6 million extraordinary gain.
• Facility Closure: Operations at the Parkside facility were closed, resulting in a $4.95 million impairment loss recognized in the prior fiscal year and ongoing write-offs of goodwill and equipment.
• Debt Extinguishment: The company repurchased subordinated debentures, recognizing gains on early extinguishment of debt.

Management Commentary and Guidance

Management intends to concentrate on its core business of radiology practice management and utilization review. Following the reporting period, the company sold its Future Diagnostics, Inc. (FDI) subsidiary for $13.5 million, expecting a gain of $12–13 million. The company also opened a new start-up operation in Oxnard, California.

Risks and Contingencies

• Litigation: The company is a defendant in a class action securities lawsuit (preliminary settlement of $240,000 pending final approval) and a new lawsuit filed in June 1997 by a physician alleging unpaid fees and seeking damages exceeding $25,000 plus potential stock conversion claims valued at $1 million.
• Liquidity: The company relies on three lines of credit totaling approximately $5.6 million outstanding as of April 30, 1997. Future debt service obligations are significant, with approximately $23.6 million due in the first year of the next five-year period.

Investor Verification Checklist

• Asset Sale Proceeds: Verify the final closing of the $16 million sale to DHS and the receipt of post-closing payments.
• FDI Transaction: Confirm the $13.5 million sale of the FDI subsidiary and the realization of the projected $12–13 million gain.
• Debt Covenants: Review compliance with the three lines of credit, particularly the collateral requirements and personal guarantees provided by the CEO.
• Legal Exposure: Monitor the status of the "Hibbard Brown" class action settlement and the new Dalrymple lawsuit regarding potential stock conversion claims.
• Reimbursement Rates: Assess the impact of decreasing reimbursement rates from Blue Shield and other payors on future revenue stability.